Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company developing proprietary drug discovery platforms and delivery systems to transform mental healthcare, announced that George Tziras, chief business officer, will present at the Jefferies Global Healthcare Conference scheduled for November 17-20, 2025, in London, United Kingdom. This presentation represents a significant opportunity for the company to showcase its progress in developing innovative mental health treatments to the global investment community.
The company is working to revolutionize mental healthcare through the development of next-generation treatment options designed to address the large unmet need for people suffering from mental health conditions. Cybin's approach focuses on creating novel drugs that provide effective and durable results for patients, positioning the company at the forefront of the emerging psychedelic medicine sector.
Cybin's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, recognizing its potential to address serious conditions where current therapies are inadequate. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder, along with a research pipeline of investigational, 5-HT-receptor focused compounds.
The presentation at this prestigious healthcare conference comes at a critical time for the psychedelic medicine industry, as companies like Cybin work to demonstrate the clinical and commercial potential of these novel treatments. With promising class-leading data, Cybin aims to change the mental health treatment landscape by introducing therapies that could offer new hope for patients who have not responded to traditional treatments.
Founded in 2019, Cybin maintains operations in Canada, the United States, the United Kingdom, and Ireland, reflecting its global approach to mental health treatment development. The company's latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN. InvestorWire, the platform disseminating this announcement, provides specialized communications services including wire-grade press release syndication and corporate communications solutions through its website at https://www.InvestorWire.com.
This conference presentation represents an important milestone for Cybin as it continues to advance its clinical programs and build investor confidence in the potential of psychedelic-based medicines to transform mental healthcare. The global healthcare investment community's interest in novel mental health treatments underscores the growing recognition of the significant market opportunity and patient need that companies like Cybin are addressing through innovative research and development.
